Refine by
Human Brain Articles & Analysis
33 news found
The level of phospholipids in the human brain begins to decline as early as when consumers reach their 20s, he said. ...
EMOTIV, the bioinformatics pioneer advancing understanding of the human brain using electroencephalography (EEG), today added two renowned scientists to its executive leadership team, naming Dr. ...
Strokes can be classified into two major categories: haemorrhagic stroke and ischemic stroke. 85% of all strokes are ischemic strokes, caused by an interruption of blood supply to the brain due to a blockage e.g., a blood clot. When the blood cannot reach the brain, brain cells die due to lack of oxygen. ...
ByBayer AG
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. ...
” Though classified as a rare disease, GBM is the most common primary brain cancer with approximately 14,000 new cases diagnosed in the United States each year, and a low median overall survival of 15-18 months after diagnosis of primary GBM.1 Glioblastomas are stage IV brain tumors – they are an exceptionally aggressive form of ...
GBM is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. ...
The Total Brain platform helps more than one million individuals improve overall mental health and brain performance using several semi-quantitative functional methods. The company’s data sets represent the world’s largest standardized brain database encompassing human electrical brain function, ...
About Nubeqa™ (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is supported ...
ByBayer AG
Basics and advanced methods of M/EEG data analysis in human brain #research will be covered extensively. Briefly, the workshop will include a journey from basic data review and pre-processing through source analysis and source imaging, arriving at connectivity analysis and group statistics. ...
About Nubeqa (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is supported by ...
ByBayer AG
About Nubeqa (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is supported by ...
ByBayer AG
ASGCT Annual Meeting Presentations and Invited Sessions Viral Engineering for the Central Nervous System Engineered AAV Capsids with Exhibit Improved Transduction of the Central Nervous System after CSF Administration Abstract No. 441 Oral Presentation – May 17; 4:00-4:15 pm ET Evaluation of a Human Neurovascular Model to Complement a Parallel ...
According to an article from Nerdist, “A team of scientists from the University of Cambridge has used the ‘mini brains’ to analyze serious maladies like lateral sclerosis and even dementia. Something they were able to do thanks to stem cells from patients themselves”. Read the full story here: ...
About Nubeqa (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is supported by ...
ByBayer AG
FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s neurologic ...
(Nasdaq: LIXT) announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated. ...
Damadian continued, “FONAR has the only MRI that has the ability to make cines (movies) of the cerebrospinal fluid (CSF) as it flows up and down the neck and around the brain in the upright, weight-loaded position. It is thanks to the UPRIGHT® MRI’s ability to scan patients in weight-bearing positions, as well as in the recumbent, non-weight-bearing position, that ...
“It’s both exciting and humbling to be a part of delivering this first-of-its-kind medicine to Parkinson’s patients, with the hope of re-innervating the human brain to make profound and lasting improvements to the quality of life for PD patients,” said Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock. “Our ...
FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s neurologic ...
FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, will ring the Nasdaq Stock Market Closing Bell on March 9, 2021. Nasdaq and FONAR selected this day as it is 50 years since the discovery of MRI by Raymond V. Damadian, M.D., FONAR’s founder and chairman, was published in the widely-read, peer-reviewed scientific journal Science on March 19, 1971.* To access the live ...